数据显示，EVM16凭借良好的安全性和耐受性、显著的免疫原性及积极的初步疗效信号，为其进一步临床开发推进提供有力支持，同时也为晚期实体瘤患者带来全新治疗希望，彰显出中国创新药在mRNA肿瘤治疗领域的重要突破。

撰文丨王聪编辑丨王多鱼排版丨水成文2020 年，mRNA 疫苗获批上市，改变了新冠疫情的发展进程。如今，这项已荣获诺贝尔奖的技术正在被用于对抗癌症——针对黑色素瘤、肺癌和膀胱癌等癌症疾病的 mRNA ...

The mRNA-based Covid vaccines helped blunt the impact of the pandemic but also sparked political backlash that has threatened ...

当前，我国恶性肿瘤发病率与死亡率居高不下，防控形势严峻。对于恶性肿瘤患者而言，术后复发如同悬顶之剑，尤其是多线治疗失败人群，仍然缺乏有效且具有针对性的治疗选择，寻求更精准、更个体化的治疗手段一直是医学界攻坚的方向。

传统观点认为，树突状细胞必须自己制造并装载抗原到自己的MHC-I上，才能激活T细胞。但研究发现，在mRNA疫苗接种后，树突状细胞直接从其他细胞，比如肌肉细胞或非造血细胞的表面“借用”了已经装好抗原的MHC-I复合物，整个搬到自己身上，再呈递给T细胞。

When U.S. Health Secretary Robert F. Kennedy Jr. announced on Aug. 5 that nearly $500 million to research mRNA vaccines would be canceled, it was one in a continuing line of moves that have put his ...

Vaccines using mRNA technology weren’t immune to the latest round of federal research cuts. Health and Human Services Secretary Robert F. Kennedy Jr. said this week that he’s pulling the plug on ...

BLOOM (TAMPA)- Dr. Kawsar Talaat, Associate Professor of Global Disease Epidemiology and Control at John’s Hopkins University, joins Casey Phillips, guest host of Bloom, guest host for Bloom, to ...

Many public health experts and scientists say they are stunned by Health Secretary Robert F. Kennedy Jr’s decision to cancel nearly half a billion dollars in federal funding for future vaccine ...

据悉， 专注于mRNA药物及递送载体技术研发的深圳深信生物科技有限公司（以下简称“深信生物”）已于今年一季度完成了数亿元A轮融资， 领跑同赛道、同轮次的融资金额。 本轮融资由CPE源峰领投，君联资本跟投，老股东智飞生物、动平衡资本、中科创星、前海母基金继续追加投资。